Correlation Between Citigroup and Egetis Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citigroup and Egetis Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and Egetis Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and Egetis Therapeutics AB, you can compare the effects of market volatilities on Citigroup and Egetis Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of Egetis Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and Egetis Therapeutics.

Diversification Opportunities for Citigroup and Egetis Therapeutics

0.05
  Correlation Coefficient

Significant diversification

The 3 months correlation between Citigroup and Egetis is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and Egetis Therapeutics AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Egetis Therapeutics and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with Egetis Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Egetis Therapeutics has no effect on the direction of Citigroup i.e., Citigroup and Egetis Therapeutics go up and down completely randomly.

Pair Corralation between Citigroup and Egetis Therapeutics

Taking into account the 90-day investment horizon Citigroup is expected to generate 1.56 times less return on investment than Egetis Therapeutics. But when comparing it to its historical volatility, Citigroup is 3.21 times less risky than Egetis Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Egetis Therapeutics AB is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  404.00  in Egetis Therapeutics AB on August 29, 2024 and sell it today you would earn a total of  137.00  from holding Egetis Therapeutics AB or generate 33.91% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy99.6%
ValuesDaily Returns

Citigroup  vs.  Egetis Therapeutics AB

 Performance 
       Timeline  
Citigroup 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.
Egetis Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Egetis Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Egetis Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Citigroup and Egetis Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citigroup and Egetis Therapeutics

The main advantage of trading using opposite Citigroup and Egetis Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, Egetis Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Egetis Therapeutics will offset losses from the drop in Egetis Therapeutics' long position.
The idea behind Citigroup and Egetis Therapeutics AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas